Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

Lung Cancer Management
doi 10.2217/lmt-2019-0011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Pcn172 - Cost-Effectiveness Analysis of Alectinib in Untreated Alk-Rearranged NSCLC Italian Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib

Journal of Community and Supportive Oncology
OncologyHematology
2016English

The Potential Role of HGF-MET Signaling and Autophagy in the War of Alectinib Versus Crizotinib Against ALK-positive NSCLC

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2018English

P044 Cost-Effectiveness Analysis of Icotinib vs Whole-Brain Irradiation in NSCLC Patients With Brain Metastases

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-39 Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn82 - Budget Impact Analysis of Alectinib for the Treatment of Patients With Untreated Alk-Rearranged NSCLC in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy